Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 916Lung Neoplasms 621Small Cell Lung Carcinoma 170Colorectal Neoplasms 133Melanoma 109Breast Neoplasms 107Neoplasms 98Ovarian Neoplasms 94Neoplasm Metastasis 90Pancreatic Neoplasms 76Squamous Cell Carcinoma of Head and Neck 70Stomach Neoplasms 60Carcinoma, Renal Cell 58Head and Neck Neoplasms 55Esophageal Neoplasms 51Endometrial Neoplasms 51Triple Negative Breast Neoplasms 50Prostatic Neoplasms 47Uterine Cervical Neoplasms 44Colonic Neoplasms 42Urinary Bladder Neoplasms 41Mesothelioma 40Carcinoma, Hepatocellular 38Mesothelioma, Malignant 37Brain Neoplasms 34Sarcoma 29Carcinoma, Transitional Cell 29Adenocarcinoma of Lung 28Lung Diseases 26Disease 26

Interventions

lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ALK Positive Non-small Cell Lung Cancer × Thoracic × 90 days × Clear all
NCT07617337 2026-06-01

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Chugai Pharmaceutical

Phase 1 Not yet recruiting
102 enrolled
Thoracic

ALK Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡